Paul A. Wagner, Ph.D., Chief Executive Officer, President and Chairperson of the Board

Dr. Wagner founded Forte, has served as President and Chief Executive Officer of Forte since 2018, and has served as a member of Forte’s board of directors since 2017. In 2017, Dr. Wagner was the Head of Corporate Strategy and Development at CANBridge Life Sciences. From 2014 to 2017, Dr. Wagner was the Chief Financial Officer of Pfenex Inc., a biotechnology company. From 2006 to 2014, Dr. Wagner held the positions of Director and Portfolio Manager/Sr. Equity Analyst with Allianz Global Investors, an investment manager where he was responsible for biotechnology and pharmaceutical investments. Prior to that, Dr. Wagner was the Head of Development Licensing at PDL BioPharma, a biopharmaceutical company from 2005 until 2006. Prior to PDL BioPharma, Dr. Wagner held the position of Vice President at Lehman Brothers, a financial services firm, starting in 1999 until 2005. Dr. Wagner received a B.S. from the University of Wisconsin and a Ph.D. in Chemistry from the California Institute of Technology. Dr. Wagner is also a Charted Financial Analyst (CFA) charter holder.

Antony A. Riley, C.P.A, Chief Financial Officer

Mr. Riley has served as Forte’s Chief Financial Officer since March 2020. Prior to joining Forte, Mr. Riley was at Krystal Biotech, Inc., a biotechnology company, from September 2017 to February 2020 where he was the Chief Financial Officer. Previously, Mr. Riley was a founding partner since 2002 of the CFO Network LLC, a consulting firm and was Acting Chief Financial Officer at Avanex Corporation and Corporate Controller at Kosan Biosciences. He also served in numerous capacities at Troy Chemical Corporation from 1997 to 2000. Mr. Riley received a B.Sc. (Honors) from the University of Bristol (England) and an M.B.A. (Honors) from the University of Chicago, Booth School of Business. Mr. Riley is a licensed CPA in the state of California.

Steven Ruhl, Chief Technical Officer

Mr. Ruhl joined Forte Biosciences in July 2021 and currently serves as the Chief Technical Officer. In this role, he is responsible for Forte’s technology and scientific needs and issues. He works with management to determine the short- and long-term technical requirements and investments to help the company reach its goals. He has over 35 years of experience in biopharmaceutical development and commercial manufacturing including technical roles with commercializing first in class products and commercial technology transfers associated with large capital projects. Before joining Forte, Mr. Ruhl supported a direct phase 3 transfer of a COVID warp speed monoclonal antibody downstream process at ThermoFisher, contributing to an accelerated PPQ campaign readiness with an external partnership and third-party sending site. Prior to that, Mr. Ruhl held positions of increasing responsibility and leadership at various biopharmaceutical companies, including IDEC Pharmaceuticals as Technical and Commercial Supply Director and Amgen as Commercial Drug Product Executive Director and Amgen Ireland Site Process Development Head. Mr. Ruhl received his B.Sc. in Microbiology and Chemistry from Brigham Young University.

Daniel J. Burge, M.D., Chief Medical Officer

Dr. Burge serves as our Chief Medical Officer and heads clinical development at Forte. Dr. Burge has 23 years of experience in the biotechnology and pharmaceutical industry. Prior to joining Forte, Dr. Burge was the Senior Vice President of Clinical Development at Dermira, Inc., a biopharmaceutical company, where he managed a Phase 3 program partnered with UCB that led to the approval of Cimzia for the treatment of psoriasis and a Phase 2 program for the treatment of atopic dermatitis. Prior to Dermira, Dr. Burge worked with Gilead Sciences, a biotechnology company, contributing to the development of novel agents for rheumatic diseases. Dr. Burge was also previously Chief Medical Officer at Trubion Pharmaceuticals, a biopharmaceutical company, Vice President of Clinical Development at Amgen, a biopharmaceutical company, and Vice President of Clinical Development at Immunex, a biopharmaceutical company. Dr. Burge received his MD from Thomas Jefferson University and his BA from Taylor University, Upland, IN.

Christopher Roenfeldt, Head of Program Management

Mr. Roenfeldt joined Forte Biosciences in October 2020 and currently serves as the Head of Program Management. In this role, he is responsible for working with management and the project teams to develop integrated programs. He has over 20 years of experience in clinical drug development including process development engineering, project management, capital construction, alliance and program management. Before joining Forte, Mr. Roenfeldt was an Alliance and Program Manager at Halozyme, overseeing multiple partnerships and development programs. Prior to that, Mr. Roenfeldt held positions of increasing responsibility and leadership at various biopharmaceutical companies, including Pfenex, Genentech and Amgen. Mr. Roenfeldt received his B.S. in Chemical Engineering from the University of Colorado.

Henry W. Talbot, Ph.D, Head of Upstream Development

Dr. Talbot is the Head of Upstream Manufacturing and Quality for Forte. Dr. Talbot has 35 years of experience in the biotechnology industry, focused on process development, manufacturing, and quality assurance. Prior to Forte, Dr. Talbot served in various roles at Pfenex Inc., a biotechnology company, including as Vice President, Quality and Facilities Operations, from 2015 to 2017 and Vice President, Research & Operations, from 2009 to 2015. Dr. Talbot was also previously a Site Leader at The Dow Chemical Company from 2007 to 2009, a Senior Leader at Dow from 1999 to 2007, a Director at Mycogen Corporation from 1992 to 1999, and had various research roles prior to joining Mycogen. Dr. Talbot received a Ph.D. in microbiology from Oregon State University, an M.S. in microbiology from the University of Missouri and a B.A. in biology from the University of Colorado.